Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...

Axi-cel is currently under priority review by the FDA ... Twinning this cutting-edge cell therapy science with the expertise of Gilead in HIV and hepatitis C therapeutics, plus its massive ...

In a tough fundraising space, cell therapy biotechs pursuing autoimmune indications review staffing to ensure the right ...

In the U.S., six non-steroidal anti-inflammatory drugs (NSAIDs) are most commonly used to manage pain and inflammation. While this drug class is widely relied upon, it is also associated with ...

This diverse educational background equipped me with a unique blend of technical, scientific, and management skills, which ...

The late-breaking poster: Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer: updated results in PD-L1 CPS ≥20 patients will be ...

In addition, HOOKIPA has partnered with Gilead to develop therapies that are intended to ... Therefore, we encourage investors, the media, and others interested in our company to review the ...

Patients with bone-predominant metastatic renal cell carcinoma (RCC) appeared to have better outcomes when they started ...

The semiconductor company exceeded expectations with an adjusted EPS of $2.69, against the expected $2.56, and revenue of $10 ...

At LSPN Fall North America, in-house counsel offered guidance on how to nail the perfect patent application. Marisa Woutersen reports.

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Biotech giant Gilead Sciences, Inc. GILD is scheduled to report third-quarter 2024 results on Nov. 6, after market close. The Zacks Consensus Estimate for sales and earnings is pegged at $6.99 ...